ABSTRACT
A 40-day-old male infant presented with fever and non-productive cough for 3 weeks, tachypnea and dyspnea 5 days before admission. The chest radiograph and computed tomographic (CT) scan revealed right lung consolidation with pleural effusion. Pleural tapping showed frank pus that grew Nocardia asteroides. The CT scan of the brain and abdomen were normal. The patient was treated with 15 mg/kg/day of trimethoprim and 75 mg/kg/day of sulfamethoxazole intravenously for 3 weeks and then orally for 6 months with complete recovery. T cell quantitative studies were normal and anti-HIV was non-reactive. A flow cytometric assay with Staphylococcal aureus and phorbol myristate acetate (PMA) as the stimulants showed normal oxidative burst which represented normal intracellular killing. One year after completion of treatment, he was healthy and the chest radiograph was normal.
Subject(s)
Empyema, Pleural/microbiology , Humans , Infant , Male , Nocardia Infections/diagnosis , Nocardia asteroides , Pneumonia, Bacterial/microbiologyABSTRACT
The MMR vaccines licensed in Thailand, Triviraten and MMR II, were used in the present study in order to evaluating their immunogenicity and safety. The study was carried out at Paholpolpayuhasena Hospital during the period from January to August 1995. Subjects comprised 116 children which were randomly divided into 2 groups. The first group (no. = 58) received Triviraten and the second group (no. = 58) received MMR II. Seroconversion rate against measles, mumps and rubella were 94.83%, 79.31% and 96.55%, respectively in the Triviraten group, and were 84.48%, 91.38% and 98.28%, respectively in the MMR II group. The differences between the seroconversion rate of three vaccine components were of no statistical significant. The geometric mean titer for the measles (1,516.07 IU/L) and mumps (1,004.45 IU/L) strain in the MMR II group, however were significantly (P < 0.001) higher than the Triviraten group. Adverse reactions from vaccination were mild and showed no statistically significant difference between the two vaccines used.